Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMPP is a great $$$$$ opportunity.
WTI > 121.68 > Brent 125.35 > futures are up.
Up, up, and away! > Let's go IMPP !
Tomorrow going to see massive volume, and 100% upside gains to .15+
Company is loaded with cash. Revenues and gross profits growing exponentially! These offerings are positive catalysts in growing company profits. Traders exited today, and investors coming on board . LET'S GO IMPP.
Also WTI and Brent moving up. Plus the shortage of refined distillates in USA will start acerbating the worldwide shortages. IMPP fleet in demand !
I still believe we see 1.24+ by closing bell, or this evening in AH.
$1.24+ by closing bell. Let's go IMPP !
Investors are forward looking > "CEO Harry Vafias discussing the "500% to 700% increase in global shipping rates for Imperial's tankers" in 2022. This means this benefit for Imperial started in Q1 2022 has grown in Q2 2022, and promises to extend into the future. The financial benefits from these higher rates have not yet been reported by Imperial. I would expect these significantly stronger results to be well received by the marketplace. In fact, the market is now revaluing Imperial shares higher."
Agree! We have seen 100M+ daily volumes. Investors are seeing company grow exponentially. The very short term offerings are beneficial to investors. IMPP tanker fleet is growing, revenues are growing, gross profits are growing. IMPP is a great $$$$$ opportunity.
IMPP > GREEN, while Markets & Crypto crash!!!!!
Funny!
Bank of America and many corporations closed on Juneteenth Day. June 20.
Juneteenth is a holiday commemorating the end of slavery in the United States. It is also called Emancipation Day or Juneteenth Independence Day. The name “Juneteenth” references the date of the holiday, combining the words “June” and “nineteenth.
All the huge Democrat controlled cities have EV scooter, and bike dealers. Sales are soaring as the 20-35 year olds see their future with out fuel combustion engine automobiles. $10.00 gallon+ on the horizon.
USA refineries not upgrading and will close one by one. Lyondell Refinery in Texas will be next one to close. It appears rationing gasoline may be on the horizon.
City DPW crews very busy striping and condoning off bike & scooter lanes.
We need a President ASAP, that can WARP SPEED the continuation of Keystone Pipeline XL . Distallate Fuels, and Nat Gas > NATIONAL PRIORITY .
In a very RED market, COGT up 60% on news.
COGT > Cogent Biosciences Says 'All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment'
7:01 am ET June 10, 2022 (Benzinga) Print
All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment
All bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cell reduction and decreases in blood KIT D816V variant allele fraction (VAF)
Bezuclastinib demonstrates favorable initial safety and tolerability profile with no reported periorbital or peripheral edema, cognitive effects or intracranial bleeding events
Cogent to host investor conference call and webcast today at 8:00 a.m. ET?
CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The data are being presented today in a poster presentation at the 2022 European Hematology Association (EHA) Congress in Vienna, Austria.
"Advanced systemic mastocytosis is a severe, debilitating hematologic disorder and physicians and patients remain in search of more effective and better tolerated treatment options to fight this disease," said Daniel DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and APEX clinical trial investigator. "I am very impressed with the early, encouraging results presented today from the APEX study. If results like these can be shown in a larger set of patients with AdvSM, I believe bezuclastinib has the potential to help us take a big step forward in treating systemic mastocytosis patients."
"We are very excited to present initial clinical data from the APEX study of bezuclastinib in advanced systemic mastocytosis," said Andrew Robbins, Chief Executive Officer at Cogent Biosciences. "These results reinforce the hypothesis that a potent, selective KIT D816V inhibitor with limited CNS penetration has the potential to provide meaningful clinical activity to all systemic mastocytosis patients, without the tolerability challenges seen with other available treatment options. Based on these results, we expect to accelerate our timelines and investment and look forward to providing another APEX clinical update by the end of 2022, and to presenting SUMMIT clinical data in non-advanced systemic mastocytosis (NonAdvSM) patients in the first half of 2023."
Data from Ongoing Phase 2 APEX Clinical Trial
APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial in patients with AdvSM evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. As of the data cutoff date of May 24, 2022, 11 patients had been treated in Part 1 at one of four dose levels (50 mg BID, 100 mg BID, 200 mg BID or 400 mg QD). The median age of patients at study entry was 70 years (ranging from 48-87 years). Patients were enrolled with the following sub-types: two patients with aggressive systemic mastocytosis (ASM), eight patients with systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and one patient with mast cell leukemia (MCL). Two patients had received prior avapritinib and midostaurin treatment.
Initial Safety Data?
As of the cutoff date, May 24, 2022, bezuclastinib was generally well-tolerated at all doses. The majority of adverse events were Grade 1/2 and seen in no more than one patient with one serious adverse event and no Grade 4 events reported. Grade 3 events reported as at least possibly related were anemia (1 patient), neutropenia (1 patient) and hypersensitivity/mediator flare (1 patient). There were no reported cases of periorbital/peripheral edema, cognitive effects or intracranial bleeding events, which have been associated with other KIT inhibitors. As of the cutoff date, all patients remained on study. Subsequently, one SM-AHN patient with chronic myelomonocytic leukemia (CMML) transformed to acute myeloid leukemia (AML) and discontinued participation in the trial.
Initial Clinical Activity Data
As of the data cutoff date of May 24, 2022, all 11 patients treated were evaluated for signs of clinical activity. Eight of 11 patients had been treated for at least two cycles, had available data from bone marrow biopsy, and were evaluated for additional endpoints Cycle 3 Day 1 (C3D1) evaluable.
11/11 patients achieved ≥50% reduction in serum tryptase levels by central assessment
89% median reduction in serum tryptase
Six of these patients achieved reduction to <20 ng/mL
8/8 patients (C3D1 evaluable) achieved ≥50% reduction in bone marrow mast cells by central review
Six of these patients achieved complete clearance of bone marrow mast cell aggregates
8/8 patients (C3D1 evaluable) demonstrated decreases in KIT D816V variant allele fraction (VAF) by droplet digital polymerase chain reaction (ddPCR)
All patients remained on treatment with treatment duration ranging from 0.5 - 4.8 months
Two patients enrolled had previously received and discontinued avapritinib for toxicity reasons (intracranial hemorrhage, thrombocytopenia). Both patients have demonstrated clinical outcomes consistent with the avapritinib-naïve patients, including similar magnitude reductions in serum tryptase.
Bezuclastinib Clinical Development?
Based on the favorable initial safety and tolerability profile and clinical activity observed to date in the Phase 2 APEX clinical trial with bezuclastinib for AdvSM,?Cogent?will continue enrolling patients in Part 1 of APEX to determine a recommended dose for use in Part 2 of the trial. A pre-planned interim analysis is scheduled once approximately 28 patients have received at least two cycles of study treatment in Part 1. Cogent plans to present additional data from APEX by the end of 2022. In addition,?Cogent continues to actively enroll?patients in SUMMIT, a Phase 2 clinical trial with bezuclastinib for NonAdvSM, and PEAK, a registrational randomized, open-label, global, Phase 3 clinical trial in patients with imatinib-resistant Gastrointestinal Stromal Tumors (GIST).?Cogent plans to present initial data from SUMMIT and lead-in data from PEAK in the first half 2023.
Conference Call Information & EHA poster
Cogent will host a webcast today at 8:00 am ET to discuss today's APEX results. The webcast will be accessible through the Investors and Media section of Cogent's website at https://investors.cogentbio.com/events. Following the live webcast, an archived replay will also be available.
Dial-in Number
U.S./Canada Dial-in Number: 844-686-3753
International Dial-in Number: 704-753-0395
Conference ID: 2951969
The APEX poster to be presented at EHA is available to registered conference attendees as well as on the Cogent
COGT up 60% @ 7.97
UPDATE: Cogent Biosciences Says 'All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment'
7:01 am ET June 10, 2022 (Benzinga) Print
All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment
All bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cell reduction and decreases in blood KIT D816V variant allele fraction (VAF)
Bezuclastinib demonstrates favorable initial safety and tolerability profile with no reported periorbital or peripheral edema, cognitive effects or intracranial bleeding events
Cogent to host investor conference call and webcast today at 8:00 a.m. ET?
CAMBRIDGE, Mass. and BOULDER, Colo., June 10, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The data are being presented today in a poster presentation at the 2022 European Hematology Association (EHA) Congress in Vienna, Austria.
"Advanced systemic mastocytosis is a severe, debilitating hematologic disorder and physicians and patients remain in search of more effective and better tolerated treatment options to fight this disease," said Daniel DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and APEX clinical trial investigator. "I am very impressed with the early, encouraging results presented today from the APEX study. If results like these can be shown in a larger set of patients with AdvSM, I believe bezuclastinib has the potential to help us take a big step forward in treating systemic mastocytosis patients."
"We are very excited to present initial clinical data from the APEX study of bezuclastinib in advanced systemic mastocytosis," said Andrew Robbins, Chief Executive Officer at Cogent Biosciences. "These results reinforce the hypothesis that a potent, selective KIT D816V inhibitor with limited CNS penetration has the potential to provide meaningful clinical activity to all systemic mastocytosis patients, without the tolerability challenges seen with other available treatment options. Based on these results, we expect to accelerate our timelines and investment and look forward to providing another APEX clinical update by the end of 2022, and to presenting SUMMIT clinical data in non-advanced systemic mastocytosis (NonAdvSM) patients in the first half of 2023."
Data from Ongoing Phase 2 APEX Clinical Trial
APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial in patients with AdvSM evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. As of the data cutoff date of May 24, 2022, 11 patients had been treated in Part 1 at one of four dose levels (50 mg BID, 100 mg BID, 200 mg BID or 400 mg QD). The median age of patients at study entry was 70 years (ranging from 48-87 years). Patients were enrolled with the following sub-types: two patients with aggressive systemic mastocytosis (ASM), eight patients with systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and one patient with mast cell leukemia (MCL). Two patients had received prior avapritinib and midostaurin treatment.
Initial Safety Data?
As of the cutoff date, May 24, 2022, bezuclastinib was generally well-tolerated at all doses. The majority of adverse events were Grade 1/2 and seen in no more than one patient with one serious adverse event and no Grade 4 events reported. Grade 3 events reported as at least possibly related were anemia (1 patient), neutropenia (1 patient) and hypersensitivity/mediator flare (1 patient). There were no reported cases of periorbital/peripheral edema, cognitive effects or intracranial bleeding events, which have been associated with other KIT inhibitors. As of the cutoff date, all patients remained on study. Subsequently, one SM-AHN patient with chronic myelomonocytic leukemia (CMML) transformed to acute myeloid leukemia (AML) and discontinued participation in the trial.
Initial Clinical Activity Data
As of the data cutoff date of May 24, 2022, all 11 patients treated were evaluated for signs of clinical activity. Eight of 11 patients had been treated for at least two cycles, had available data from bone marrow biopsy, and were evaluated for additional endpoints Cycle 3 Day 1 (C3D1) evaluable.
11/11 patients achieved ≥50% reduction in serum tryptase levels by central assessment
89% median reduction in serum tryptase
Six of these patients achieved reduction to <20 ng/mL
8/8 patients (C3D1 evaluable) achieved ≥50% reduction in bone marrow mast cells by central review
Six of these patients achieved complete clearance of bone marrow mast cell aggregates
8/8 patients (C3D1 evaluable) demonstrated decreases in KIT D816V variant allele fraction (VAF) by droplet digital polymerase chain reaction (ddPCR)
All patients remained on treatment with treatment duration ranging from 0.5 - 4.8 months
Two patients enrolled had previously received and discontinued avapritinib for toxicity reasons (intracranial hemorrhage, thrombocytopenia). Both patients have demonstrated clinical outcomes consistent with the avapritinib-naïve patients, including similar magnitude reductions in serum tryptase.
Bezuclastinib Clinical Development?
Based on the favorable initial safety and tolerability profile and clinical activity observed to date in the Phase 2 APEX clinical trial with bezuclastinib for AdvSM,?Cogent?will continue enrolling patients in Part 1 of APEX to determine a recommended dose for use in Part 2 of the trial. A pre-planned interim analysis is scheduled once approximately 28 patients have received at least two cycles of study treatment in Part 1. Cogent plans to present additional data from APEX by the end of 2022. In addition,?Cogent continues to actively enroll?patients in SUMMIT, a Phase 2 clinical trial with bezuclastinib for NonAdvSM, and PEAK, a registrational randomized, open-label, global, Phase 3 clinical trial in patients with imatinib-resistant Gastrointestinal Stromal Tumors (GIST).?Cogent plans to present initial data from SUMMIT and lead-in data from PEAK in the first half 2023.
Conference Call Information & EHA poster
Cogent will host a webcast today at 8:00 am ET to discuss today's APEX results. The webcast will be accessible through the Investors and Media section of Cogent's website at https://investors.cogentbio.com/events. Following the live webcast, an archived replay will also be available.
Dial-in Number
U.S./Canada Dial-in Number: 844-686-3753
International Dial-in Number: 704-753-0395
Conference ID: 2951969
COGT
Yup!
> For the rest of us GTOR is a table pounder!
T-U-E-S-D-A-Y >>>>> $$$$$ > GTOR
Wake up pal! Clueless and lost in the shuffle! Looking @ .20+ on Tuesday!
Top of the morning to all GTOR folks! > By closing bell Tuesday, we should be > .20+
Potential opening bell gapper > .06+
Marathon Digital Holdings Announces Bitcoin Production and Mining Operation Updates for May 2022
Although we continue to install miners at the Texas facilities, we have experienced delays in energization as Compute North’s energy provider awaits federal agency confirmation of its exempt status for tax purposes based upon its arrangements with Compute North,” said Fred Thiel, Marathon’s chairman and CEO. “While these delays have been disappointing, our current understanding is that miners should start to come online this month. We continue to work closely and actively engage with Compute North to gain more insight into the energy provider’s timeline and to ensure that these delays, once resolved, will not impact our future deployments.
“In the meantime, installations of our miners have progressed irrespective of the energization schedule. Currently, in addition to our active fleet, we now have 19,000 miners, representing approximately 1.9 EH/s, that have been installed and ready for energization. Over 9,000 of these units, representing 0.9 EH/s, are at Compute North’s first major facility in West Texas. The remainder are installed at other locations. This first major facility is being completed in four stages. Stage one is already complete. It is our understanding that the entire facility, which will house approximately 68,000 of our miners, will be fully constructed with all miners in installed by the end of the third quarter of 2022.
“These energization delays in Texas, coupled with ongoing maintenance issues at the power generating station in Hardin, MT, negatively impacted our bitcoin production last month. In May, maintenance issues at the power generation station in Montana caused us to produce approximately 47% less bitcoin than what would have been expected based on the network’s hash rate during the month. However, we believe that our production results will improve over time as we move forward with our deployment plan and energize our miners installed in Texas.
“We remain confident that Marathon is well positioned to achieve its performance goals, and we will continue to provide updates as they materialize. We have a strong foundation from which to build, we have a solid pipeline of potential hosting and power arrangements that exceeds our needs and allows us to diversify our operations, and we have a strong balance sheet to support our growth plans. We look forward to continuing to execute on our strategy of achieving carbon neutrality by the end of this year and growing to 23.3 EH/s in early 2023.”
Cash on hand was approximately $59.6 million and total liquidity, now defined as unrestricted cash and available credit facilities, was approximately $86 million.
Marathon’s current bitcoin holdings is approximately $315.1 million.
IT'S now like free agency . Players jump on best offers. Just like Tom Brady.
In October, Aaron Judge is a free agent > Some team could offer him several hundred million contract.
Tiger Woods turnrd down $900M . from LIV > I think Tiger will have ongoing issues with his leg injury . So sore from the surgery metals . He will probably never win again!
The GGTOOR is like today's start of LIV Golf Tour. > Both are about BIG MONEY!
GTOR is about being at the right place at the right time!
May see an upside gap @ opening bell. Liking the fundamental and technical indicators here.
Getting closer > "On June 14, 2022, the Company will launch GGTOORCITY in a Metaverse. GGTOORCITY will be comprised of 2,145 commercial parcels of land in the Metaverse that will produce a total of 4,144 commercial and residential parcels.”
GTOR
At BYU , McMahon was on the 10th story dormitory floor. He got beer hammered on night. And one fraternity challenged him to jump from one balcony to another balcony on same floor. Jim did it !!!!! But still breaks out in a sweat today when reminiscing about that CRAZY DARE.
Regardless, let's go GATORS !
GTOR
You buying, or waiting for 6's >
Next TUESDAY > Certain and specific parcels will go on sale Tuesday, June 14, 2022, at 9:00 AM EST with prices ranging from $375,000 to $28,000,000 per parcel. The less expensive city parcels with prices starting at $8,400 will be released for sale at a future date.
Also I followed crazy Jim McMahon who was the quarterback of one of the best teams of the 1980s – the 1985 Chicago Bears.
GTOR running on a huge offensive stake in Metaverse.
I am accumulating faster. > I excited about next Tuesday!
Man-o-man! Your like Michael Jordan of the old Chicago Bulls! Big Bucks > $$$$$
LOL, now that's one hell of a greeting. Got shares, but slowly accumulating my stake here.
Hey tomj1, I see you have been actively accumulating shares!